Tenofovir DF + Lamivudine + Efavirenz Tablets (300 mg + 300 mg + 600 mg)
Tenofovir DF + Lamivudine + Efavirenz is a fixed-dose triple combination pairing two NRTIs with a non-nucleoside reverse transcriptase inhibitor (NNRTI), forming a complete first-line antiretroviral regimen in a single daily tablet. The format is endorsed for public-health programme use.
Indicated for the treatment of HIV-1 infection in adults and adolescents weighing at least 40 kg, as a complete single-tablet antiretroviral regimen, particularly in treatment-naïve patients in resource-limited and high-burden settings.
Disclaimer
The content on this website is for general informational purposes only. While we strive for accuracy, RV Group makes no warranties regarding the completeness, reliability, or suitability of the information. For detailed product specifications, regulatory documentation, or inquiries, please contact us directly.
Our Tenofovir DF + Lamivudine + Efavirenz Tablets (300 mg + 300 mg + 600 mg) are also Available for
FAQ on Tenofovir DF + Lamivudine + Efavirenz Tablets (300 mg + 300 mg + 600 mg)
Everything You Need to Know About RV Groups
RV Group operates through four integrated business verticals, each designed to create value across the pharmaceutical ecosystem.
Our Business
Quick Links
Contact
- hello@opv.vn
- +1 800 555 25 65